Lithium, by inhibiting inositol phosphate metabolism, interferes with the phosphatidylinositol ("phosphoinositide") cycle, which is stimulated by numerous hormones and neurotransmitters. To examine the relevance of this action to neurotransmission, we evaluated effects of lithium treatment on smooth muscle responses to transmitters. In lithiumpretreated tracheal muscle, the relaxation following carbachol or histamine contractions is retarded. Lithium does not affect relaxation following contractions elicited by treatment with KCI and phorbol 12,13-diacetate in combination, which bypasses receptor stimulation of the phosphatidylinositol cycle. Half-maximal effects of lithium occur at 1 mM, corresponding to therapeutic concentrations. Dampening of neurotransmitter responses by lithium treatment may explain the unique ability of lithium to relieve and prevent both mania and depression.
Lithium is a major therapeutic agent in affective disorder, exerting both prophylactic and acute therapeutic action in mania and in some forms of depression (1). Studies of the mechanism of action of lithium have focused upon its effects on biogenic amine neurotransmitters (2, 3) , which are involved in actions of antidepressant drugs and may play a role in the pathophysiology of affective disorder (4) . The ability of lithium to affect the phosphatidylinositol (PtdIns) system, which is stimulated by biogenic amine neurotransmitters, has led recently to suggestions that interference with this cycle may mediate lithium's therapeutic action (5, 6) .
The PtdIns cycle is a major second-messenger system mediating actions of numerous hormones and neurotransmitters (7) (8) (9) . Receptor stimulation triggers the cleavage of phosphatidylinositol 4,5-bisphosphate, giving rise to diacylglycerol and inositol 1,4,5-trisphosphate (Fig. 1) . Inositol trisphosphate mobilizes intracellular calcium, while diacylglycerol activates protein kinase C by enhancing its affinity for calcium which stimulates protein kinase C activity. Phosphatase enzymes sequentially remove phosphate groups from inositol trisphosphate, giving rise to free inositol which is then converted to phosphatidylinositol bisphosphate to reinitiate the Ptdlns cycle.
Inhibition by lithium of phosphatase activity causes a buildup of various inositol phosphates (6) . In principle, this action could slow down the PtdIns cycle and thus dampen cellular responses to neurotransmitters. However, the relevance of this effect of lithium to its therapeutic action is unclear, since in most systems employed to evaluate lithium's action on phosphatidylinositol phosphates, 5-10 mM lithium is used, higher than the therapeutic serum levels of lithium, about 1 mM (1). Moreover, evidence is lacking that lithium's effect on the PtdIns cycle actually alters cellular response to neurotransmitters. The PtdIns system mediates contractile responses to neurotransmitters in smooth muscle. In a wide variety of smooth muscle preparations, receptor-mediated stimulation of the PtdIns cycle by neurotransmitters and inositol trisphosphate-induced release of calcium from intracellular stores have been documented (7, (9) (10) (11) (12) (13) (14) . Also, we have demonstrated potent actions of phorbol esters, which activate protein kinase C (15, 16) , on contractile responses in smooth muscle (17, 18) . To test the hypothesis that lithium's inhibition of inositol phosphate turnover alters the physiological response to transmitters, we sought a smooth muscle system in which the PtdIns cycle could be maximally stimulated and the contractile response maintained so that any slowdown in the cycle could be reflected in the contractile response. In smooth muscle preparations such as the guinea pig ileum and pulmonary artery, neurotransmitter-elicited Abbreviation: PtdIns, phosphatidylinositol.
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contractions fade with persistent stimulation. However, sustained contractions elicited by muscarinic cholinergic stimulation are readily elicited in the guinea pig trachea. Since its contractile response to muscarinic stimulation is largely independent of extracellular calcium (19, 20) , the trachea is particularly well-suited for investigating lithium's effects on the PtdIns cycle which is thought to be involved in mediating contractile response to agonists in this tissue (12, 21) . Using this preparation, we found that lithium in therapeutic concentrations dampens responses to neurotransmitter stimulation.
METHODS
Trachea from male guinea pigs (300-500 g) were dissected free of surrounding tissue and cut transversely into segments of 1-3 adjacent tracheal rings. Three segments were tied into a chain and hung in a 25-ml tissue bath containing 95 or 115 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 2.5 mM CaCl2, 1.2 mM KH2PO4, 25 mM NaHCO3, and 11.6 mM glucose. This buffer was kept at 370C and continuously bubbled with 5% CO2 in oxygen. One end of the chain was fixed, and the other was attached to a Grass force-displacement transducer for isometric measurements of tension. Initial resting tension was set at =2 g. The tissue was allowed to equilibrate for at 100. 
RESULTS
Maximal contractions of the trachea were elicited by incubation with 40 ,uM carbachol, a concentration that strongly stimulates the PtdIns cycle (11), for 2 hr in either the presence or the absence of 3 mM lithium. Tension during this incubation was not affected by lithium. However, at the end of 2 hr, the relaxation initiated by washing carbachol from the tissue with multiple, rapid changes of the incubation fluid was prolonged in tissues incubated with lithium. In the absence of lithium, relaxation to 50% of the tension occurred by about 5 min. In contrast, in lithium-treated samples, relaxation is markedly slowed, with a 50% decrease in tension at 12 min ( Fig. 2A) .
To determine whether the contractile response to carbachol stimulation is altered by this treatment, tissues were rechallenged with carbachol at 1 uM. Lithium has no effect on the amplitude or rate of rise of the carbachol response, indicating that lithium's effect is selective for relaxation.
Relaxation following incubation with carbachol can also be initiated by atropine, a selective muscarinic antagonist. With this method, relaxation times are more rapid and reproducible than when carbachol is diluted by repeated changes ofthe incubation buffer. Even more striking prolongation of the relaxation phase is produced by lithium when atropine is used. After a 2-hr incubation of tissue with 40 AM carbachol, 4 ,uM atropine was added to initiate relaxation. Tissue incubated with both carbachol and 3 mM lithium required 3.4 times longer to relax by 90% than those exposed to carbachol alone (n = 4). This ratio increased to 4.8 with 40 ,uM atropine (n = 7; Fig. 3 ). Even at the higher concentrations, atropine is still a selective antagonist, as it does not affect contractions produced by prostaglandin F2a.
To assess the dependence of this effect on the concentration of lithium, tissues were incubated with 40 ,uM carbachol and a range of lithium concentrations for 2 hr. Some prolon- [Lii, mM preparations) in the times required to achieve 90% relaxation (to.9) produced by lithium is shown for each contractile stimulus.
gation of relaxation was observed at 0.5 mM lithium, and a half-maximal effect occurred at about 1 mM (Fig. 3) .
Prolonged relaxation is not restricted to the recovery from muscarinic cholinergic stimulation. We observed a similar effect of lithium on the relaxation following histamineinduced contractions (Table 1) .
We wondered whether the effect of lithium is restricted to receptor-mediated responses or might occur with any type of contraction. Stimulation of protein kinase C with phorbol esters, when combined with potassium depolarization, also produces a large sustained contraction ofthe guinea pig trachea (18) . Relaxation following a 2-hr maximal contraction produced by bypassing receptor stimulation in this manner was not affected by 3 mM lithium, indicating that lithium's effect is selective for receptor-mediated events ( Fig. 2B ; Table 1) .
In other experiments, we examined the time course for the actions of lithium (Fig. 4) . The relaxation slowed slightly following exposure to carbachol alone for 30 min or longer. However, a 1-hr incubation with lithium and carbachol further prolonged relaxation. Maximal influence occurred at 2 hr and no further increase was observed with 4 hr of incubation. Incubation with lithium alone for 2 hr did not alter the relaxation following a brief exposure to carbachol. Addition of lithium just prior to atropine did not alter the relaxation rate. Thus, to ensure maximal effects of lithium, the incubation medium must include both carbachol and lithium during this period. Lithium's effect on relaxation was most apparent when contraction was elicited by 40 (11) . Since a variety of inositol phosphates accumulate during lithium treatment (23) (24) (25) (26) (27) (28) , it is unclear whether inositol trisphosphate or other inositol phosphates are primarily involved.
Muscarinic stimulation inhibits relaxation of tracheal smooth muscle produced by activation of the adenylate cyclase system (29) . We also found that incubation with carbachol prolonged relaxation in control tissues (Fig. 4) . Therefore, one can view lithium's action as a further large enhancement of carbachol's ability to retard relaxation.
Although these studies utilized smooth muscle, the similarity of neurotransmitter actions on the PtdIns cycle in the brain and peripheral tissues argues that lithium effects on neurotransmitter responses mediated by the PtdIns system occur also in brain, especially since lithium at therapeutic levels does cause accumulation of inositol phosphates in brain in vivo (5, 25, 30) . In electrophysiological studies using the hippocampal slice preparation, we have found that low concentrations of lithium also alter neuronal cholinergic responses (unpublished observations). In contrast to other drugs that either stimulate or depress mood, the "normalizing" ability of lithium to relieve both mania and depression has been difficult to explain. Since lithium's effect appears to depend on the level ofactivation ofthe PtdIns system, lithium should be most effective at sites where the PtdIns system is overactive, which may differ in mania and depression. Transmitters affected would include all those known to act via the PtdIns cycle, including norepinephrine, serotonin, acetylcholine, histamine, and several peptides. This "second-messenger" concept of the actions of lithium fits better with the normalizing effects of lithium than would influences on any single transmitter. If lithium's interference with the PtdIns cycle accounts for its therapeutic action in affective disorder, we suggest that chemicals that potently and selectively inhibit inositol phosphate metabolism may also be therapeutically active. 
